Biocon Ltd

Biocon Earnings Call Transcript: Key Takeaways

Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.

Biocon Management Change

Biocon's board recorded the resignation of Chief Technology Officer Mandar Ghatnekar, effective 31 December 2026. Mukesh Rathi is appointed CTO, effective 1 January 2027.

Biocon Other Announcement

Biocon Limited informed the Exchange of shareholder communications regarding the withholding of FY 2025-26 final dividends for missing mandatory KYC and bank details.

Biocon Investor Presentation: Key Takeaways

Q2 FY27 revenue from operations ₹4,389 Cr (+2% YoY), EBITDA ₹865 Cr (20% margin vs 22%), reported PAT ₹41 Cr (−52% YoY). Management expects a stronger H2.

Biocon Results Update

Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.

Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY

Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.

Key figure

Net profit ₹56.7 Cr · -57.3% YoY

Biocon Board Meeting Date

Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.

Biocon Business Update

Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.

Biocon Other Announcement

Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From

Genentech

Biocon Legal & Regulatory

Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.

Value

₹3.21 Cr

Biocon Employee Stock Options

Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.

Biocon Business Update

Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.

Biocon Bags New Order from Bahiafarma and Bionovis

Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.

From

Bahiafarma and Bionovis (Brazil PDP program)

Execution

10 years

Biocon Other Announcement

Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.

Biocon Capital Structure Change

Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.

Biocon Regulatory Approval

Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.

Biocon Business Update

Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.